14-hydroxyclarithromycin has been researched along with clarithromycin in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (5.45) | 18.7374 |
| 1990's | 37 (67.27) | 18.2507 |
| 2000's | 10 (18.18) | 29.6817 |
| 2010's | 4 (7.27) | 24.3611 |
| 2020's | 1 (1.82) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, Y; Grosset, J; Perronne, C; Pocidalo, JJ; Truffot-Pernot, C; Vilde, JL | 1 |
| Chen, HY; Maskell, JP; Powell, M | 1 |
| Azoulay-Dupuis, E; Bédos, JP; Pocidalo, JJ; Vallée, E; Veber, B | 1 |
| Chu, SY; Craft, C; Guay, DR; Wilson, DS | 1 |
| Cavanaugh, JC; Chu, S; Locke, C; Park, Y; Wilson, DS | 1 |
| Hoffman, BM; Olsson-Liljequist, B | 1 |
| Dabernat, H; Delmas, C; Fourtillan, JB; Girault, J; Lareng, MB; Seguy, M | 1 |
| Azoulay-Dupuis, E; Bergogne-Bérézin, E; Pocidalo, JJ; Swanson, R; Vallée, E | 1 |
| Andrews, JM; Ashby, JP; Logan, MN; Wise, R | 1 |
| Chen, HY; Powell, M; Weinhardt, B; Williams, JD | 1 |
| Howell, AW; Jorgensen, JH; Maher, LA | 1 |
| Gu, JW; Neu, HC; Scully, BE | 1 |
| Barry, AL; Fuchs, PC; Pfaller, MA | 1 |
| Chu, SY; Sennello, LT; Sonders, RC | 1 |
| Clement, JJ; Hardy, DJ; Marsh, K; Rode, RA; Shipkowitz, NL; Swanson, RN | 1 |
| Barrett, MS; Erwin, ME; Jones, RN | 1 |
| Adachi, T; Iwasaki, H; Kamiya, N; Morimoto, S; Watanabe, Y | 1 |
| Fernandes, PB; Freiberg, L; Ramer, N; Rode, RA | 1 |
| Adachi, T; Kondoh, H; Morimoto, S; Nagate, T; Sota, K; Watanabe, Y | 1 |
| Biehle, JR; Cavalieri, SJ; Sanders, WE | 1 |
| Cederbrant, G; Kahlmeter, G; Kamme, C; Schalén, C | 1 |
| Larsson, AJ; Rotschafer, JC; Walker, KJ; Zabinski, RA | 1 |
| Beyer, J; Capobianco, J; Flamm, R; Goldman, RC; Zakula, D | 1 |
| Danziger, LH; Fish, DN; Gotfried, MH; Rodvold, KA | 1 |
| Bedford, KA; Bowker, K; Holt, HA; MacGowan, AR; Reeves, DS | 1 |
| Cole, PJ; Kees, F; Read, RC; Roberts, P; Tsang, KW; Wilson, R | 1 |
| Cederberg, A; Sundberg, L | 1 |
| Demartini, G; Dugnani, S; Fraschini, F; Galmozzi, G; Sandelli, M; Scaglione, F | 1 |
| Chu, SY; Decourt, JP; Fourtillan, JB; Girault, J; Granneman, GR; Pichotta, PJ | 1 |
| Coles, SJ; James, I; Kearsley, NJ; Macklin, JL | 1 |
| Beyer, J; Clement, J; Flamm, RK; Tanaka, SK | 1 |
| Carr, R; Chu, SY; Gan, VN; McCarty, JM | 1 |
| Anderson, DE; Eiland, J; Garrison, MW; Malone, CL | 1 |
| Danziger, LH; Gotfried, MH; Rodvold, KA; Servi, RJ | 1 |
| Danziger, LH; Meyer, JM; Pendland, SL; Ryu, S | 1 |
| Chen, C; Danziger, LH; Martin, SJ; Pendland, SL; Schreckenberger, PC | 1 |
| Amsden, GW; Cheng, KL; Nafziger, AN; Peloquin, CA | 1 |
| Martin, SJ; Pendland, SL | 1 |
| Amsden, GW; Garey, KW; Godo, PG; Nafziger, AN; Peloquin, CA | 1 |
| Bergman, KL; Fey, PD; Olsen, KM; Peddicord, TE; Rupp, ME | 1 |
| Danziger, LH; Jung, R; Losendahl, KJ; Messick, CR; Pendland, SL; Schriever, CA; Tesoro, EP | 1 |
| Butts, JD; Ives, TJ; Majerus, TC; Marston, EL; Regnery, RL | 1 |
| Bayliff, CD; Bombassaro, AM; McCormack, DG; Nolan, T; Offman, E; Varin, F | 1 |
| Boruchoff, SE; Deutsch, PJ; Grasing, KW; Kusma, SE; McCrea, J; Seibold, JR; Sturgill, MG; Winchell, GA | 1 |
| Caliendo, G; De Nucci, G; Lerner, FE; Santagada, V | 1 |
| Garvin, CG; Martin, SJ; McBurney, CR; Sahloff, EG | 1 |
| Allewelt, M; Beyer, G; Borner, K; Burkhardt, O; Lode, H; Nord, CE; Stass, H | 1 |
| De Paepe, E; De Pauw, M; Hoetelmans, RM; Lefebvre, E; Sekar, VJ; Spinosa-Guzman, S; Vangeneugden, T | 1 |
| Chen, X; Li, S; Zhang, X; Zhong, D; Zou, M | 1 |
| Alffenaar, JW; de Velde, F; Greijdanus, B; Uges, DR; Wessels, AM | 1 |
| Oswald, S; Peters, J; Siegmund, W; Venner, M | 1 |
| Block, W; Freyer, J; Grube, M; Kroemer, HK; Lämmer, M; Lütjohann, D; Oswald, S; Peters, J; Siegmund, W; Venner, M | 1 |
| Block, W; Eggers, K; Lämmer, M; Lütjohann, D; Oswald, S; Peters, J; Siegmund, W; Venner, M | 1 |
| Alffenaar, JW; Greijdanus, B; Koster, RA; Uges, DR; Vu, DH; Wessels, AM | 1 |
| Chin, MC; Choi, YK; Ghim, JL; Jung, J; Kim, B; Kim, S; Lee, J; Shin, JG; Song, GS | 1 |
13 trial(s) available for 14-hydroxyclarithromycin and clarithromycin
| Article | Year |
|---|---|
Drug-food interaction potential of clarithromycin, a new macrolide antimicrobial.
Topics: Absorption; Administration, Oral; Adult; Biological Availability; Chromatography, High Pressure Liquid; Clarithromycin; Erythromycin; Fasting; Food; Humans; Male | 1992 |
Penetration of clarithromycin and its 14-hydroxy metabolite into middle ear effusion in children with secretory otitis media.
Topics: Child; Child, Preschool; Clarithromycin; Female; Haemophilus influenzae; Humans; Infant; Male; Moraxella catarrhalis; Nasopharynx; Otitis Media with Effusion; Streptococcus pneumoniae; Streptococcus pyogenes | 1994 |
A single-blind, randomised, comparative study of clarithromycin and amoxycillin suspensions in the treatment of children with lower respiratory tract infections.
Topics: Amoxicillin; Bacterial Infections; Child; Child, Preschool; Clarithromycin; Female; Humans; Infant; Male; Respiratory Tract Infections; Single-Blind Method; Suspensions | 1993 |
Penetration of clarithromycin into middle ear fluid of children with acute otitis media.
Topics: Acute Disease; Anti-Bacterial Agents; Child; Child, Preschool; Clarithromycin; Ear, Middle; Female; Humans; Infant; Male; Otitis Media with Effusion | 1997 |
Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Bronchoalveolar Lavage Fluid; Clarithromycin; Drug Administration Schedule; Epithelium; Female; Humans; Lung; Macrophages, Alveolar; Male; Middle Aged | 1997 |
Oral cimetidine prolongs clarithromycin absorption.
Topics: Absorption; Administration, Oral; Adult; Anti-Bacterial Agents; Cimetidine; Clarithromycin; Cross-Over Studies; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Male; Time Factors | 1998 |
Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers.
Topics: Adult; Anti-Asthmatic Agents; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Cross-Over Studies; Drug Interactions; Female; Humans; Indoles; Leukotriene Antagonists; Male; Phenylcarbamates; Sulfonamides; Tosyl Compounds | 1999 |
The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Area Under Curve; Calcium; Chromatography, High Pressure Liquid; Clarithromycin; Cross-Over Studies; Drug Interactions; HIV Protease Inhibitors; Humans; Indinavir; Male; Uric Acid | 2000 |
Clarithromycin bioequivalence study of two oral formulations in healthy human volunteers.
Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Biotransformation; Calibration; Clarithromycin; Cross-Over Studies; Female; Humans; Male; Mass Spectrometry; Quality Control; Reference Standards; Reproducibility of Results; Solutions; Therapeutic Equivalency | 2000 |
Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Aza Compounds; Clarithromycin; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Tolerance; Feces; Fluoroquinolones; Half-Life; Humans; Intestines; Male; Metabolic Clearance Rate; Moxifloxacin; Oropharynx; Quinolines; Saliva | 2002 |
Darunavir/ritonavir pharmacokinetics following coadministration with clarithromycin in healthy volunteers.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Chromatography, High Pressure Liquid; Clarithromycin; Cross-Over Studies; Darunavir; Dose-Response Relationship, Drug; Drug Combinations; Female; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir; Sulfonamides; Time Factors | 2008 |
LC-MS/MS method for the simultaneous determination of clarithromycin, rifampicin and their main metabolites in horse plasma, epithelial lining fluid and broncho-alveolar cells.
Topics: Animals; Anti-Bacterial Agents; Biotransformation; Bronchioles; Bronchoalveolar Lavage Fluid; Chromatography, High Pressure Liquid; Clarithromycin; Drug Interactions; Drug Stability; Horse Diseases; Horses; Limit of Detection; Pulmonary Alveoli; Reproducibility of Results; Respiratory Tract Infections; Rifampin; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2011 |
Pharmacokinetics and Pharmacodynamics of Tegoprazan Coadministered With Amoxicillin and Clarithromycin in Healthy Subjects.
Topics: Adult; Amoxicillin; Area Under Curve; Benzene Derivatives; Clarithromycin; Dose-Response Relationship, Drug; Drug Combinations; Gastrointestinal Agents; Healthy Volunteers; Humans; Hydrogen-Ion Concentration; Imidazoles; Male; Metabolic Clearance Rate; Middle Aged | 2021 |
42 other study(ies) available for 14-hydroxyclarithromycin and clarithromycin
| Article | Year |
|---|---|
Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages.
Topics: Anti-Infective Agents; Clarithromycin; Drug Combinations; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Minocycline; Mycobacterium avium; Quinolones | 1992 |
Protective efficacy of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae in a murine septicaemia model.
Topics: Animals; Bacteremia; Clarithromycin; Disease Models, Animal; Drug Synergism; Erythromycin; Female; Haemophilus Infections; Haemophilus influenzae; Mice; Mice, Inbred BALB C | 1992 |
Individual efficacy of clarithromycin (A-56268) and its major human metabolite 14-hydroxy clarithromycin (A-62671) in experimental pneumococcal pneumonia in the mouse.
Topics: Animals; Clarithromycin; Erythromycin; Female; Lung; Mice; Microbial Sensitivity Tests; Pneumonia, Pneumococcal | 1992 |
Clarithromycin pharmacokinetics in healthy young and elderly volunteers.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Chromatography, High Pressure Liquid; Clarithromycin; Creatinine; Female; Humans; Male; Metabolic Clearance Rate | 1992 |
In-vitro activity of clarithromycin combined with its 14-hydroxy metabolite A-62671 against Haemophilus influenzae.
Topics: Clarithromycin; Drug Therapy, Combination; Erythromycin; Haemophilus influenzae; Microbial Sensitivity Tests | 1991 |
The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal tests.
Topics: Clarithromycin; Drug Therapy, Combination; Erythromycin; Female; Haemophilus influenzae; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Serum Bactericidal Test; Species Specificity | 1991 |
Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Erythromycin; Female; Haemophilus Infections; Haemophilus influenzae; Lung Diseases; Mice; Mice, Inbred C57BL | 1991 |
The in-vitro and disc susceptibility testing of clarithromycin and its 14-hydroxy metabolite.
Topics: Bacteria; Blood Proteins; Clarithromycin; Drug Evaluation, Preclinical; Drug Therapy, Combination; Erythromycin; Microbial Sensitivity Tests; Protein Binding | 1991 |
In-vitro cidal activity of clarithromycin and its 14-hydroxy metabolite (A-62671) against Haemophilus influenzae.
Topics: Clarithromycin; Drug Evaluation, Preclinical; Drug Therapy, Combination; Erythromycin; Haemophilus influenzae; Microbial Sensitivity Tests; Time Factors | 1991 |
Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae.
Topics: Clarithromycin; Drug Resistance, Microbial; Erythromycin; Haemophilus influenzae; Humans; Microbial Sensitivity Tests | 1991 |
Bactericidal activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae and streptococcal pathogens.
Topics: Administration, Oral; Clarithromycin; Erythromycin; Haemophilus influenzae; Humans; Serum Bactericidal Test; Streptococcus; Streptococcus pneumoniae; Streptococcus pyogenes | 1991 |
Susceptibility of Haemophilus influenzae to clarithromycin alone and in combination with its 14-hydroxy metabolite.
Topics: Clarithromycin; Drug Therapy, Combination; Erythromycin; Haemophilus influenzae; Microbial Sensitivity Tests | 1991 |
Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high-performance liquid chromatography with electrochemical detection.
Topics: Chromatography, High Pressure Liquid; Clarithromycin; Electrochemistry; Erythromycin; Humans | 1991 |
Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.
Topics: Animals; Clarithromycin; Drug Synergism; Erythromycin; Female; Gerbillinae; Haemophilus Infections; Haemophilus influenzae; Microbial Sensitivity Tests; Otitis Media | 1990 |
In vitro activity of clarithromycin (TE-031, A-67268) and 14OH-clarithromycin alone and in combination against Legionella species.
Topics: Clarithromycin; Drug Therapy, Combination; Erythromycin; Legionella; Microbial Sensitivity Tests | 1990 |
Crystal and molecular structure of (14R)-14-hydroxy-6-O-methylerythromycin A.
Topics: Clarithromycin; Crystallization; Erythromycin; Molecular Structure; X-Ray Diffraction | 1989 |
Bioassay for A-56268 (TE-031) and identification of its major metabolite, 14-hydroxy-6-O-methyl erythromycin.
Topics: Biological Assay; Chromatography, High Pressure Liquid; Clarithromycin; Erythromycin; Humans; Micrococcus | 1988 |
14-Hydroxy-6-O-methylerythromycins A, active metabolites of 6-O-methylerythromycin A in human.
Topics: Chemical Phenomena; Chemistry; Clarithromycin; Erythromycin; Humans; Molecular Conformation | 1988 |
Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant | 1995 |
Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori.
Topics: Amoxicillin; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Erythromycin; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Metronidazole; Microbial Sensitivity Tests; Omeprazole | 1994 |
Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Clarithromycin; Clavulanic Acids; Drug Synergism; Drug Therapy, Combination; Haemophilus influenzae; Humans; Kinetics; Microbial Sensitivity Tests; Models, Biological | 1994 |
Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes.
Topics: Centrifugation, Density Gradient; Clarithromycin; Erythromycin; Escherichia coli; Helicobacter pylori; Indicators and Reagents; Ribosomes | 1994 |
Penetration of clarithromycin into lung tissues from patients undergoing lung resection.
Topics: Adolescent; Adult; Aged; Chromatography, High Pressure Liquid; Clarithromycin; Female; Humans; Lung; Male; Middle Aged | 1994 |
Synergy testing of macrolide combinations using the chequerboard technique.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Haemophilus influenzae | 1993 |
The concentrations of clarithromycin and its 14-hydroxy metabolite in sputum of patients with bronchiectasis following single dose oral administration.
Topics: Administration, Oral; Adult; Aged; Bronchiectasis; Clarithromycin; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Sputum | 1994 |
The postantibiotic effect of clarithromycin and its major human metabolite, 14-hydroxy clarithromycin.
Topics: Bacteria; Clarithromycin; Humans | 1993 |
Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics.
Topics: Chromatography, High Pressure Liquid; Clarithromycin; Half-Life; Humans; Liver Diseases; Metabolic Clearance Rate; Middle Aged | 1993 |
Kill kinetics of antimicrobial agents against Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Ciprofloxacin; Clarithromycin; Helicobacter pylori; Humans; Kinetics; Logistic Models; Metronidazole; Microbial Sensitivity Tests; Organometallic Compounds | 1996 |
Influence of pH on the antimicrobial activity of clarithromycin and 14-hydroxyclarithromycin against Haemophilus influenzae using an in vitro pharmacodynamic model.
Topics: Clarithromycin; Colony Count, Microbial; Exudates and Transudates; Haemophilus influenzae; Humans; Hydrogen-Ion Concentration; Lung; Microbial Sensitivity Tests; Models, Biological; Otitis Media with Effusion; Reproducibility of Results | 1997 |
In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori.
Topics: Amoxicillin; Bismuth; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Helicobacter pylori; Microbial Sensitivity Tests; Organometallic Compounds; Salicylates | 1997 |
In vitro activity of clarithromycin alone and in combination with ciprofloxacin or levofloxacin against Legionella spp.: enhanced effect by the addition of the metabolite 14-hydroxy clarithromycin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Clarithromycin; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Humans; In Vitro Techniques; Legionella; Legionella pneumophila; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin | 1997 |
Bactericidal activity and postantibiotic effect of clarithromycin and 14-hydroxyclarithromycin, alone and in combination, against Legionella pneumophila.
Topics: Anti-Bacterial Agents; Clarithromycin; Colony Count, Microbial; Drug Therapy, Combination; Legionella pneumophila; Microbial Sensitivity Tests | 1998 |
Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Endothelium, Vascular; Haemophilus influenzae; Humans; Streptococcus pneumoniae | 1999 |
Postantibiotic effects and bactericidal activities of clarithromycin-14-hydroxy-clarithromycin, versus those of amoxicillin-clavulanate, against anaerobes.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacteroides fragilis; Clarithromycin; Colony Count, Microbial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Peptostreptococcus | 2000 |
In vitro susceptibilities of Rickettsia and Bartonella spp. to 14-hydroxy-clarithromycin as determined by immunofluorescent antibody analysis of infected vero cell monolayers.
Topics: Animals; Anti-Bacterial Agents; Bartonella; Chlorocebus aethiops; Clarithromycin; Fluorescent Antibody Technique; Microbial Sensitivity Tests; Rickettsia; Tetracycline; Vero Cells | 2000 |
Oral absorption of clarithromycin in acute illness and during convalescence in patients with community-acquired pneumonia.
Topics: Absorption; Acute Disease; Administration, Oral; Aged; Anti-Bacterial Agents; Clarithromycin; Community-Acquired Infections; Convalescence; Female; Humans; Male; Mouth Mucosa; Pneumonia, Bacterial; Prognosis; Prospective Studies; Radiography; Severity of Illness Index | 2000 |
The activity of 14-hydroxy clarithromycin, alone and in combination with clarithromycin, against penicillin- and erythromycin-resistant Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Clarithromycin; Colony Count, Microbial; Drug Combinations; Drug Resistance, Multiple; Erythromycin; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Streptococcus pneumoniae | 2001 |
Bioavailability of clarithromycin cyclodextrin ternary complexes upon oral administration to healthy beagle dogs.
Topics: Administration, Oral; Animals; Area Under Curve; beta-Cyclodextrins; Biological Availability; Chromatography, High Pressure Liquid; Citric Acid; Clarithromycin; Dogs; Female; Hydrogen-Ion Concentration; Male; Mass Spectrometry; Solubility | 2008 |
Simultaneous determination of clarithromycin, rifampicin and their main metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: Anti-Bacterial Agents; Chromatography, Liquid; Clarithromycin; Humans; Rifampin; Tandem Mass Spectrometry | 2009 |
Oral absorption of clarithromycin is nearly abolished by chronic comedication of rifampicin in foals.
Topics: Absorption; Animals; ATP-Binding Cassette Transporters; Bronchi; Cholesterol; Clarithromycin; Drug Interactions; Epithelial Cells; Horses; Hydroxycholesterols; Lung; Mouth Mucosa; Multidrug Resistance-Associated Protein 2; Organic Anion Transporters; Pregnane X Receptor; Receptors, Steroid; Rifampin; RNA, Messenger | 2011 |
Clarithromycin is absorbed by an intestinal uptake mechanism that is sensitive to major inhibition by rifampicin: results of a short-term drug interaction study in foals.
Topics: Animals; Clarithromycin; Drug Interactions; Female; HEK293 Cells; Horses; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Lung; Male; Organic Anion Transporters; Respiratory Mucosa; Rifampin; Transfection; Up-Regulation | 2012 |
Troubleshooting carry-over of LC-MS/MS method for rifampicin, clarithromycin and metabolites in human plasma.
Topics: Chromatography, Liquid; Clarithromycin; Humans; Linear Models; Reproducibility of Results; Rifampin; Sensitivity and Specificity; Tandem Mass Spectrometry | 2013 |